EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:
“We’re excited to share the latest findings from the EORTC Brain Tumour Group, exploring TMZ treatment in older adults glioblastoma patients with a truly unmethylated MGMT promoter.
TMZ treatment showed no benefit in this specific patient group, challenging current treatment protocols and paving the way for more personalised therapies.”
Read further.
Source: EORTC/LinkedIn